Qelbree Scheduling Status
No, Qelbree (viloxazine extended-release) is not a Schedule 2 medication—it is a non-controlled, nonstimulant medication without evidence of drug dependence or abuse potential. 1
Key Distinguishing Features
Viloxazine functions as a selective norepinephrine reuptake inhibitor with serotonin-norepinephrine modulating properties, representing a nonstimulant treatment option that does not carry the abuse liability associated with Schedule 2 stimulants. 2
Unlike CNS stimulants (methylphenidate, amphetamines) which are Schedule 2 controlled substances with high potential for abuse and severe psychological/physical dependence, viloxazine is a non-stimulant medication without evidence of drug dependence. 1
Clinical Implications
This non-controlled status makes Qelbree a suitable alternative to standard-of-care stimulant pharmacotherapy for ADHD, particularly for patients where stimulant abuse potential is a concern or where stimulants are contraindicated. 1
Prescribers can write standard prescriptions without the restrictions required for Schedule 2 medications (no refills, written prescriptions in many states, quantity limitations). 1
The medication was FDA-approved in April 2021 for pediatric ADHD (ages 6-17 years) and subsequently for adults, with its safety profile and pharmacokinetics well understood from its historical use as an antidepressant. 1
Common Pitfall to Avoid
- Do not confuse the recommendation to consider adding a stimulant medication (which ARE Schedule 2) to existing Qelbree therapy for residual ADHD symptoms with Qelbree's own scheduling status—Qelbree itself remains non-controlled. 3